Summary
Multiple drug-label-relevant clinical/pharmacologic claims are not directly supported by the provided FDA label excerpts (e.g., market/sales statements; specific adherence/market-competition claims; some mechanistic claims are only partially supported by the label). No explicit indication/dosing/safety statements from the AI response can be fully evaluated because the response set does not include label-anchored wording for all categories.
Category Scores
Accurate Statements
Leqvio is a PCSK9 inhibitor developed by Novartis.
Supported only in part: label excerpt describes inclisiran mechanism involving PCSK9 mRNA degradation. The 'developed by Novartis' and 'PCSK9 inhibitor' branding are not stated in provided label excerpts.
Leqvio targets and lowers PCSK9 protein levels.
Mechanism: inclisiran directs breakdown of PCSK9 mRNA; this supports PCSK9 protein reduction as a consequence, but the label excerpts provided state mRNA breakdown and increased LDL-C receptor recycling/expression rather than explicitly 'PCSK9 protein levels' phrasing.
PCSK9 reduces the liver's ability to remove LDL cholesterol from the blood.
Not directly supported in the provided label excerpts.
By inhibiting PCSK9, Leqvio increases the number of LDL receptors on liver cells.
Mechanism of action excerpt: RNA interference increases LDL-C receptor recycling and expression, which increases LDL-C uptake and lowers LDL-C levels.
Increasing LDL receptors on liver cells leads to more effective clearance of LDL cholesterol.
Mechanism excerpt supports increased LDL-C uptake and lowered LDL-C levels; 'clearance' phrasing is not explicitly used.
Leqvio is effective in lowering LDL cholesterol.
Clinical studies section excerpt and indication context support LDL-C reduction; specific efficacy magnitude not provided in excerpts.
Leqvio competes in the PCSK9 inhibitor market with Praluent (alirocumab).
Not supported in provided label excerpts.
Leqvio competes in the PCSK9 inhibitor market with Repatha (evolocumab).
Not supported in provided label excerpts.
Unsupported Statements
Leqvio generated $1.746 billion in sales in 2023.
Sales figures are not present in the provided FDA label excerpts.
Leqvio sales in 2022 were $931 million.
Sales figures are not present in the provided FDA label excerpts.
Leqvio sales increased by 87% in 2023 compared to the previous year.
Derived sales metrics are not present in the provided FDA label excerpts.
In the fourth quarter of 2023, Leqvio had net sales of $573 million.
Sales figures are not present in the provided FDA label excerpts.
Leqvio net sales in the fourth quarter of 2023 increased by 42% compared to the same period in 2022.
Derived sales metrics are not present in the provided FDA label excerpts.
Leqvio has a convenient dosing regimen.
Label excerpt provides dosing interval, but 'convenient' is not a label claim.
Leqvio is a non-statin option.
The provided label excerpts do not state 'non-statin option' wording.
Leqvio addresses an unmet need for patients who cannot tolerate statins.
The provided label excerpt does not mention statin intolerance or unmet need framing.
Leqvio addresses an unmet need for patients who require additional lipid-lowering therapy.
The indication excerpt specifies adjunct to diet and exercise and labeled populations, but does not use 'unmet need' framing.
Leqvio is administered as a twice-yearly injection schedule that contributes to patient adherence.
Label excerpt supports every-6-month dosing schedule, but 'contributes to patient adherence' is not stated.
PCSK9 reduces the liver's ability to remove LDL cholesterol from the blood.
Not stated in the provided label excerpts.
Leqvio competes in the PCSK9 inhibitor market with Praluent (alirocumab).
Market comparison is not stated in the provided label excerpts.
Leqvio competes in the PCSK9 inhibitor market with Repatha (evolocumab).
Market comparison is not stated in the provided label excerpts.
Praluent and Repatha target LDL cholesterol reduction.
Not stated in the provided label excerpts for LEQVIO.
Leqvio's efficacy has been demonstrated in the phase III ORION program.
The provided label excerpts do not mention 'ORION' by name.
In the ORION program, Leqvio reduced LDL cholesterol levels when added to statin therapy.
Provided label excerpts do not mention ORION or statin background in the provided text.
In the ORION program, Leqvio reduced LDL cholesterol levels as monotherapy.
Provided label excerpts do not mention ORION or monotherapy outcomes in the provided text.
In the ORION program, patients had hypercholesterolemia.
Provided label excerpts do not mention ORION or this program-level description.
Studies have highlighted that Leqvio provides benefit in reducing cardiovascular risk.
The provided label excerpts do not mention cardiovascular risk reduction benefit.
Contradictions
Important Omissions
For contraindications/warnings: the AI response does not mention the label-specific contraindication of prior serious hypersensitivity to inclisiran or excipients, and does not mention hypersensitivity reactions (anaphylaxis/angioedema) as warnings/precautions.
Importance:
Moderate
Administration instructions beyond schedule: label specifies subcutaneous injection by a healthcare professional and injection sites/avoid active skin disease/injury; the AI response only provides a schedule-adherence claim and omits these instruction details.
Importance:
Moderate
Label indications precision: the AI response does not specify the labeled patient populations (adults with hypercholesterolemia; adults and pediatric patients ≥12 with HeFH; pediatric patients ≥12 with HoFH) as written in the label excerpt.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only safety-relevant label topic in the AI response is absent; however, the evaluated statements are mostly non-safety marketing/science claims. Missing explicit hypersensitivity contraindication/warning details is an omission rather than a direct contradiction.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Many claims (sales figures, market competition, ORION program specifics, cardiovascular risk benefit, adherence wording, statin intolerance/unmet need framing) are not supported by the provided FDA label excerpts. Mechanism statements are partially aligned but include unsupported/label-inconsistent phrasing (e.g., PCSK9 functional description).
Suggested Improvement
Restrict claims to the provided label excerpt wording: labeled indications (hypercholesterolemia/HeFH/HoFH with ages), dosing schedule (284 mg at baseline, 3 months, then every 6 months), mechanism details (PCSK9 mRNA breakdown; LDL-C receptor recycling/expression; LDL-C uptake and lowering), and label safety items (contraindication for serious hypersensitivity to inclisiran/excipients; reported hypersensitivity reactions). Remove unsupported sales, market competition, ORION-phase naming, cardiovascular risk benefit, and statin intolerance/unmet-need framing unless present in label excerpts.